Dose dependence of fetal malformations associated with valproate

Neurology

Volumn 81, Issue 11, 2013, Pages 999-1003

  Vajda, Frank J ^a   O'Brien, Terence J ^a   Graham, Janet E ^a   Lander, Cecilie M ^b   Eadie, Mervyn J ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID;

ADULT; ARTICLE; AUSTRALIA; CLEFT LIP PALATE; DISEASE ASSOCIATION; DISEASE REGISTRY; DOSE RESPONSE; FEMALE; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; HEART SEPTUM DEFECT; HUMAN; HYPOSPADIAS; INCIDENCE; MAJOR CLINICAL STUDY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGENY; SPINAL DYSRAPHISM;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; AUSTRIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; FETAL DISEASES; HUMANS; HYPOSPADIAS; LOGISTIC MODELS; MALE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; REGISTRIES; RETROSPECTIVE STUDIES; SPINAL DYSRAPHISM; VALPROIC ACID;

EID: 84884571836     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a43e81     Document Type: Article

References (24)

1. Robert E, Guibaud P. Maternal valproic acid and congenital neural-tube defects. Lancet 1982;2:937.
2. Samrén EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739-746.
3. Tomson T, Battino D. Teratogenicity of antiepileptic drugs: state of the art. Curr Opin Neurol 2005;18:135-140.
4. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012;11:803-813.
5. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010;362:2185-2193.
6. Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antieptileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:981-990.
7. Omtzigt JG, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(4 suppl 5):119-125.
8. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-158.
9. Mawer G, Clayton-Smith J, Coyle H, Kini U. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 2002;11:512-518.
10. Vajda FJ, O'Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004;11:854-858.
11. Meador KJ, Baker JA, Finnell RH, et al. In utero fetal drug exposure: fetal death and malformations. Neurology 2006; 67:407-412.
12. Morrow J, Russell A, Guthrie E, et al. Malformation risk of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiat 2006;77:193-198.
13. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-617.
14. Ornoy A. Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod Toxicol 2006;22:214-226.
15. Vajda FJ, O'Brien TJ, Graham J, Lander CM, Eadie MJ. Associations between particular types of fetal malformation and antiepileptic drug exposure in utero. Acta Neurol Scand Epub 2013 Mar 6.
16. Vajda F, O'Brien T, Hitchcock A, Graham J, Lander C, Eadie M. The Australian pregnancy register of antiepileptic drugs: aspects of data collection and analysis. J Clin Neurosci 2007;14:936-942.
17. Riley M, Halliday J. Birth Defects in Victoria 1983-1998. Melbourne: Perinatal Data Collection Unit, Victorian Government Department of Human Services; 2000.
18. Vajda FJ, Hollingworth S, Graham J, et al. Changing patterns of antiepileptic drug use in pregnant Australian women. Acta Neurol Scand 2009;121:89-93.
19. Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999;40:1231-1236.
20. Philbert A, Pederson B, Dam M. Concentration of valproate during pregnancy, in the newborn and in breast milk. Acta Neurol Scand 1985;72:460-463.
21. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology 1992;42(4 suppl 5):12-16.
22. Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. Urinary excretion of valproate and some metabolites in chronically treated patients. Ther Drug Monit 1989;11:127-133.
23. Omtzigt JG, Nau H, Los FJ, Pijpers L, Lindhout D. The disposition of valproate and its metabolites in the late first trimester and early second trimester of pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, comedication, and the presence of spina bifida. Eur J Clin Pharmacol 1992;43:381-388.
24. Rettenmeier AW, Gordon WP, Prickett KS, et al. Metabolic fate of valproic acid in the Rhesus monkey: formation of a toxic metabolite, 2-n-propyl-pentenoic acid. Drug Metab Dispos 1986;14:443-453.